Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer

Summary

The purpose of this phase II study is to see if gene transfer with or without pembrolizumab therapy shrinks tumors.

General Information

NCT#: NCT03412877
Study ID: 180049
Trial Phase: Phase II

Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Aldesleukin, Fludarabine, Pembrolizumab, Autologous tumor infiltrating lymphocytes (TIL)

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search